Bio/Pharma Business

Exothera Partners with Remedium to Scale-Up Manufacturing of Gene Therapy Drug Candidate

March 30, 2023

CDMO Exothera and biotech company Remedium are joining forces to scale up the manufacturing process for Remedium’s lead gene therapy candidate for treating osteoarthritis.

Takeda to Invest ¥‎100 Billion (US$754 Million) into New Plasma Therapy Manufacturing Facility

March 30, 2023

Takeda plans to build a new facility in Osaka, Japan, for the manufacture of plasma-derived therapies.

US Supreme Court Weighs Biologics Patents in Amgen vs. Sanofi Case

March 30, 2023

The Supreme Court heard oral arguments concerning the legitimacy of “genus clauses” in bio/pharma patents.

Illuminating the State of Outsourcing with Stephen Houldsworth (DCAT 2023)

March 27, 2023

Stephen Houldsworth, VP and Head of Platform Management & Marketing at CordenPharma, dives into ongoing trends in the outsourcing space.

Ingredion Announces Strategic Investments in India Expanding into High-Value Pharmaceutical Ingredients

March 27, 2023

Ingredion has completed two strategic investments in India with Amishi Drugs & Chemicals and Mannitab Pharma Specialties.

Harm Reduction Therapeutics and Catalent Sign Commercial Supply Agreement

March 24, 2023

Harm Reduction Therapeutics and Catalent have signed a commercial supply agreement for naloxone nasal spray to reverse opioid overdoses.

Invitae and Deerfield Management Team Up on Novel Therapeutics for Rare Diseases

March 22, 2023

Under a new partnership, Invitae and Deerfield Management will harness genetic and clinical testing data from patients to discover potential novel therapeutics for treating rare diseases.

Sanofi Drops Lantus US List Price by 78%, Capping Out-of-Pocket Costs at $35

March 21, 2023

Sanofi intends to cut its US list price for Lantus (insulin glargine injection) by 78% and cap out-of-pocket costs at $35 for all patients with commercial insurance.

BioNTech and OncoC4 to Co-Develop mAb for Solid Tumor Indications

March 21, 2023

BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.

Sartorius and Teknova Team Up for Gene Therapy Process Development

March 21, 2023

Sartorius BIA Separations and Teknova will collaborate to combine their technologies in an effort to streamline the downstream purification process.